Emerging trends in pharmaceutical design and drug manufacturing are shifting toward presenting the market with new ways to develop medications. Specialty medications continue to be a major area of pharmaceutical development and have become widely discussed in workers’ comp due to their significant costs. Although they represent approximately 1% of drug utilization, they account for nearly 7% of prescription drug costs and represent the fastest-growing segment of the U.S. pharmaceutical market. While specialty drug products are often associated with a hefty price tag, some can offer clinical advantages when deployed for the right patient at the right time, making careful oversight and patient selection imperative to achieving desired outcomes in this space. Watch the video blog to learn more.
More stories
Enlyte Announces Customer and Market Operations Leadership Transition
P&C veteran Keith Higdon assumes Enlyte CMO president position as Nina Smith transitions to vice chairman role, maintaining leadership continuity
A Checklist of 8 Support Team Qualities to Look for When Choosing a Casualty Solutions Software Vendor
The quality of a vendor’s software product support team matters as much as the solution itself. Whether you are asking a routine question or navigating a critical issue, the right support team can make the difference between a quick resolution and ongoing disruption.
Enlyte’s Dave Torrence Explains Why Integration Is Key to Managing Workers’ Comp Costs
Dave Torrence of Enlyte shares why integrating claims services, clinical solutions, and technology is key to controlling workers’ comp costs and improving outcomes.
Specialty Solutions Spotlight: Why Translation Matters in Workers’ Compensation
Language diversity is a significant consideration in the effective management of workers’ compensation claims because non-English or Limited English Proficient (LEP) employees are disproportionately represented in high-injury industries such as construction, agriculture, manufacturing and food service.
California Utilization Review Regulation Updates Effective April 1, 2026
Overview of California DWC rule changes impacting utilization review, MPN physicians, treating physician changes, and the MTUS drug formulary, effective April 1, 2026.
The Direct PT Paradox: Better Outcomes, Lower Adoption
In the most recent Risk & Insurance article, Kim Radcliffe explores how direct access to physical therapy improves workers' compensation outcomes while traditional referral processes create costly delays. Discover evidence-based approaches that enhance recovery and control costs.